WilmerHale Advises Syros Pharma in Initial Public Offering

WilmerHale Advises Syros Pharma in Initial Public Offering

Firm News

WilmerHale advised Syros Pharmaceuticals, Inc., a life sciences company, in its initial public offering. The company intends to use the proceeds to fund its proof-of-concept Phase II clinical trial of SY-1425 in acute myelogenous leukemia and myelodysplastic syndrome, including clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs. The offering is expected to close on July 6, 2016, subject to customary closing conditions.
 
The WilmerHale team on the transaction was led by Partner Steven Singer and included Special Counsel Cynthia Mazareas, Senior Associate Stephanie Singer and Associate Killian Nolan.

Read Syros Pharmaceuticals' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.